Fw Tin Từ
AMA Morning Round
Gs Trịnh Nguyễn Đàm Giang thông
tin
Study indicates fenofibrate may reduce need for
laser treatment of retinopathy among patients with Type 2 diabetes.
MedPage Today (11/8, Bankhead) reports, "Patients
with type 2 diabetes given fenofibrate for lipid lowering required significantly
less laser treatment for retinopathy," according to study published
online in The Lancet. Lead author Anthony Keech, M.D., of the University
of Sydney, and colleagues, "reviewed data" from a previous study,
"which examined almost 10,000 patients with type 2 diabetes. The
trial evaluated fenofibrate's ability to reduce the risk of macrovascular
and microvascular events compared with placebo (Lancet 2005; 366: 1849-1861)."
They found that "[treatment with fenofibrate did not reduce the risk
of a two-step progression in retinopathy in the entire cohort, or in the
subgroup of patients without retinopathy at baseline." However, "patients
with pre-existing retinopathy had a significant reduction in risk with
fenofibrate compared with placebo (3.1% versus 14.6%, P=0.004)."
The researchers concluded, "The substantial benefits of fenofibrate
on the need for laser treatment for diabetic retinopathy are likely to
be additive to those benefits arising from tight control of blood glucose
and blood pressure in the management of type 2 diabetes, and emerge rapidly
after treatment is commenced."
Inflammation may cause insulin resistance which triggers Type 2 diabetes,
researchers say.
The UPI (11/8) reports that "inflammation -- and not obesity -- initiates
insulin resistance that is the major cause of Type 2 diabetes," according
to a University of California at San Diego School of Medicine study published
in the Nov. 7 issue of the journal Cell Metabolism. Investigators conducting
research in "mouse models" found that "inflammation provoked
by immune cells called macrophages leads to insulin resistance."
